249 related articles for article (PubMed ID: 14600095)
1. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
[TBL] [Abstract][Full Text] [Related]
2. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
4. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
Xu L; Eiseman JL; Egorin MJ; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):185-219. PubMed ID: 14571691
[TBL] [Abstract][Full Text] [Related]
6. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; RamÃrez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
10. Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
Hardcastle A; Boxall K; Richards J; Tomlin P; Sharp S; Clarke P; Workman P; Aherne W
Assay Drug Dev Technol; 2005 Jun; 3(3):273-85. PubMed ID: 15971989
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Chung YL; Troy H; Kristeleit R; Aherne W; Jackson LE; Atadja P; Griffiths JR; Judson IR; Workman P; Leach MO; Beloueche-Babari M
Neoplasia; 2008 Apr; 10(4):303-13. PubMed ID: 18392140
[TBL] [Abstract][Full Text] [Related]
13. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.
Machida H; Nakajima S; Shikano N; Nishio J; Okada S; Asayama M; Shirai M; Kubota N
Cancer Sci; 2005 Dec; 96(12):911-7. PubMed ID: 16367912
[TBL] [Abstract][Full Text] [Related]
17. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
[TBL] [Abstract][Full Text] [Related]
18. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
[TBL] [Abstract][Full Text] [Related]
20. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
Maloney A; Workman P
Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
